Replies to post #105471 on Biotech Values

[DewDiligence]

Thanks for posting about Astellas’ YM150. Now I’ll have to update the compilation in #msg-54934658 again :- )

As can be seen from the slide in #msg-53285279, YM150 is pretty far behind Pradaxa, Xarelto, and Apixaban in most indications.

clinicaltrials.gov shows that the phase-2 RUBY-1 trial in ACS (http://clinicaltrials.gov/ct2/show/study/NCT00994292 ) and the phase-2 OPAL-2 trial in AF (http://clinicaltrials.gov/ct2/show/study/NCT00938730 ) are still recruiting patients, even though both trials should have been fully enrolled by now. Neither of these trials has any trial sites in the US.